Primary biliary cholangitis (PBC) is a chronic cholestatic liver disease associated with autoimmune phenomena targeting intrahepatic bile duct cells (cholangiocytes). Although its etiopathogenesis remains obscure, development of antimitochondrial autoantibodies against pyruvate dehydrogenase complex E2 is a common feature. MicroRNA (miR) dysregulation occurs in liver and immune cells of PBC patients, but its functional relevance is largely unknown. We previously reported that miR-506 is overexpressed in PBC cholangiocytes and directly targets both Cl -/HCO 2 3 anion exchanger 2 and type III inositol 1,4,5-trisphosphate receptor, leading to cholestasis. Here, the regulation of miR-506 gene expression and its role in cholangiocyte pathophysiology and immune activation was studied. Several proinflammatory cytokines overexpressed in PBC livers (such as interleukin-8 [IL8], IL12, IL17, IL18, and tumor necrosis factor alpha) stimulated miR-506 promoter activity in human cholangiocytes, as revealed by luciferase reporter assays. Experimental overexpression of miR-506 in cholangiocytes dysregulated the cell proteomic profile (by mass spectrometry), affecting proteins involved in different biological processes including mitochondrial metabolism. In cholangiocytes, miR-506 (1) induced dedifferentiation with down-regulation of biliary and epithelial markers together with up-regulation of mesenchymal, proinflammatory, and profibrotic markers; (2) impaired cell proliferation and adhesion; (3) increased oxidative and endoplasmic reticulum stress; (4) caused DNA damage; and (5) sensitized to caspase-3-dependent apoptosis induced by cytotoxic bile acids. These events were also associated with impaired energy metabolism in mitochondria (proton leak and less adenosine triphosphate production) and pyruvate dehydrogenase complex E2 overexpression. Coculture of miR-506 overexpressing cholangiocytes with PBC immunocytes induced activation and proliferation of PBC immunocytes. Conclusion: Different proinflammatory cytokines enhance the expression of miR-506 in biliary epithelial cells; miR-506 induces PBC-like features in cholangiocytes and promotes immune activation, representing a potential therapeutic target for PBC patients.
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inefficient; and the first-line treatment approved by the Food and Drug Administration is the daily administration of ursodeoxycholic acid (UDCA), which improves prognosis in approximately two thirds of patients when treated in early stages of the disease. (1, 2) UDCA is a hepatoprotective bile acid that promotes choleresis by stimulating the hepatobiliary secretion of bicarbonate, which further induces the alkalinization and fluidization of bile and prevents the damaging effect of hydrophobic bile acids on the biliary epithelium. (1, 2) Cholestasis in PBC patients is linked to impaired biliary bicarbonate secretion. (3, 4) The main bicarbonate extruder in normal human cholangiocytes is the Cl -/ HCO 2 3 anion exchanger 2 (AE2), which is located in the apical membrane promoting secretin-stimulated biliary bicarbonate secretion and regulating intracellular pH homeostasis.
(5-7) PBC patients show a lack of response to secretin associated with decreased expression of AE2 in cholangiocytes, which results in cholestasis. (8) However, UDCA treatment restores the secretin response and improves cholestasis in PBC patients. The etiopathogenic role of the characteristic AE2 down-regulation in both liver and peripheral blood mononuclear cells (PBMCs) of PBC patients is highlighted by the fact that Ae2 -/-mice spontaneously develop several hepatobiliary and immunological PBC-like features, including AMA specific against PDC-E2. (9) Expression of AE2 in cholangiocytes becomes up-regulated under the combination of UDCA and glucocorticoids, treatment employed for patients who do not respond to UDCA monotherapy. (6) On the other hand, type 3 inositol 1,4,5-trisphosphate receptor (InsP3R3) is an integral membrane protein located in the subapical portion of the endoplasmic reticulum (ER) of cholangiocytes that functions as a major Ca 21 i release channel, and its activation promotes biliary bicarbonate secretion. (10, 11) Like AE2, expression of InsP3R3 was also found down-regulated in PBC cholangiocytes promoting cholestasis. Notably, the characteristic downregulation of both AE2 and InsP3R3 in PBC cholangiocytes is mediated, at least partially, by microRNA-506 (miR-506), which directly targets both AE2 and InsP3R3 mRNAs in cholangiocytes, leading to impaired biliary secretory functions. (8, 12) Therefore, miR-506 seems to have a pivotal role in the etiopathogenesis of PBC, but the mechanisms regulating its expression in cholangiocytes and the direct functional effects of miR-506 in cholangiocytes are still unknown.
In this study, we investigated the role of different factors-such as proinflammatory cytokines, bile acids, and estrogens-in the regulation of miR-506 expression in cholangiocytes. Moreover, the effect of miR-506 in cholangiocyte pathophysiology and in PBC immune regulation was studied.
Materials and Methods

LUCIFERASE REPORTER CONSTRUCTS AND ASSAYS
Three fragments of different sizes of the human miR-506 gene (hsa-miR-506; National Center for Biotechnology Information no. 574511) promoter (i.e., 3,229, 1,936, or 993 bp of the 5 0 -flanking region of hsa-miR-506 [Z1-hsa-miR-506pr, Z2-hsa-miR506pr, and Z3-hsa-miR-506pr, respectively]) were cloned in a luciferase expression vector as described in Supporting Fig. S1A ,B and Supporting Table S1 . Next, nontumor SV40-immortalized human cholangiocytes (i.e., H69, a gift from Dr. D. Jefferson, Tufts University, Boston, MA) were transfected with Z1, Z2, or Z3 recombinant vectors using Lipofectamine 2000 (Life Technologies) as described in the Supporting Information. The transfection mix was replaced 6 hours later by Dulbecco's modified Eagle medium-1 10% fetal bovine serum alone or together with different proinflammatory cytokines (i.e., interleukin 1beta [IL1b], IL6, IL8, IL12, IL17, IL18, tumor necrosis factor alpha [TNFa] , and interferon gamma [IFNc]), profibrotic factors (i.e., transforming growth factor beta 1), estrogens (i.e., 17b-estradiol), glucocorticoids (i.e., dexamethasone), growth factors (i.e., epidermal growth factor), and bile acids (i.e., cholic acid, UDCA, and tauroursodeoxycholic) (Supporting Table S2 ). Then, 24 hours after transfection, 50 mL of lysis buffer was added into each well, and luciferase activity was assessed (in 20 mL of cell homogenate) using the Luciferase Assay Kit E151A (Promega). Luciferase activity was measured in a NOVOstar Apparatus (BMG Labtech), and the resultant values were normalized to the total protein concentration.
STABLE OVEREXPRESSION OF miR-506 IN HUMAN CHOLANGIOCYTES
H69 human cholangiocytes were stably transfected with recombinant vectors containing miR-506 (H69-miR-506) or miRNA-negative (H69-miR-neg) control sequence (Thermo Fisher Scientific) or just with vehicle (H69), as we described. (12) Then, transfected cells were continuously selected with blasticidin (Invitrogen) in fully supplemented Dulbecco's modified Eagle medium nutrient mixture F-12 medium. (13) GENE AND miR-506 EXPRESSION Gene and miR-506 expression was quantified as described (8) and as detailed in the Supporting Information. Primer sequences are shown in Supporting Table S3 .
MASS SPECTROMETRY
Shotgun comparative proteomic analysis of H69, H69-miR-neg, and H69-miR-506 cells was performed using isobaric tags for relative and absolute quantitation). (14) Peptide labeling, peptide fractionation, and mass spectrometric analysis were performed as described (15) (see Supporting Information for technical details). After tandem mass spectrometric analysis, protein identification and relative quantification were performed with the ProteinPilot software (version 4.5; Sciex) using the Paragon algorithm as the search engine. (16) Although relative quantification and statistical analysis were provided by the ProteinPilot software, an additional 1.3-fold change cutoff for all isobaric tags for relative and absolute quantitation ratios (<0.77 or > 1.3) and a P value < 0.05 were selected to classify proteins as up-regulated or downregulated. Functional analysis of proteins was determined by gene ontology enrichment using the Panther Classification System database (http://pantherdb.org/).
IMMUNOBLOTTING
Protein expression was analyzed as described in Supporting Information and using the antibodies listed in Supporting Table S4 .
CELL PROLIFERATION, ADHESION, AND MIGRATION
Cell proliferation, adhesion, and migration were evaluated in H69, H69-miR-neg, and H69-miR-506 cholangiocytes as described in Supporting Information.
OXIDATIVE STRESS
Dihydroethidium staining was used to detect reactive oxygen species (ROS) in H69, H69-miR-neg, and H69-miR-506 cholangiocytes. For this purpose, 2 3 10 4 cells per well were seeded in coverslips in 24-well plates and grown for 48 hours. Cells were stained with 15 lM dihydroethidium (Molecular Probes, Thermo Fisher) for 10 minutes at 378C in darkness, fixed with 1% paraformaldehyde in phosphatebuffered saline, and mounted using Vectashield (Vector Laboratories). Pictures were taken using a fluorescence microscope (Leica DM IRB).
CELL VIABILITY AND APOPTOSIS
The cytotoxicity of the hydrophobic bile acids chenodeoxycholic acid (CDCA, 200 mM; Sigma) and glycochenodeoxycholic acid (750 mM; Sigma) was evaluated in H69, H69-miR-neg, and H69-miR-506 cholangiocytes. Additionally, caspase-mediated apoptosis and necroptosis were investigated by incubating cells with specific inhibitors (zVAD-fmk and necrostatin-1, respectively, at 20 mM; both from Calbiochem). Cell viability was evaluated using both CellTiter-Glo (Promega) and WST-1 (Roche) assays, following the manufacturers' instructions. Apoptotic rates of cholangiocytes were measured by flow cytometry using Annexin V Alexa Fluor 594 conjugate (Thermo Fisher Scientific) and propidium iodide (Life Technologies) in a Guava Easycyte 8HT apparatus. See Supporting Information for further details.
MITOCHONDRIAL METABOLIC ACTIVITY
The oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) were measured in an XF96 Extracellular Flux Analyzer (Seahorse Bioscience) using the XF Cell Mito Stress Test Kit, following the manufacturer's instructions (Supporting Fig. S2 ).
ADENOSINE TRIPHOSPHATE PRODUCTION
Levels of adenosine triphosphate (ATP) in H69, H69-miR-neg, and H69-miR-506 cholangiocytes were measured using the ATP Assay Kit (Abcam). Cells were harvested, and 3 3 10 6 cholangiocytes were processed following the manufacturer's instructions. Triplicates were used in each assay. Absorbance was measured at 570 nm in a Multiskan Ascent spectrophotometer (Thermo).
IMMUNOFLUORESCENCE
Expression of PDC-E2 was evaluated by immunofluorescence in H69, H69-miR-neg, and H69-miR-506 cholangiocytes as described in Supporting Information.
COCULTURE OF HUMAN CHOLANGIOCYTES WITH PBMCs
H69, H69-miR-neg, and H69-miR-506 human cholangiocytes were cocultured with PBMCs isolated from both normal and PBC individuals, and then immune activation (CD25; BD Biosciences) and proliferation (CellTrace CFSE Cell Proliferation Kit; Invitrogen) were evaluated by flow cytometry as described in the Supporting Information. The supernatants of the different cell cultures and cell cocultures were harvested, and cytokine levels (i.e., IL17A and IL23) were evaluated using the Milliplex Map Human High Sensitivity T Cell Panel-Immunology Multiplex Assay (Millipore), following the manufacturer's instructions. The research protocol was approved by the Ethical Committee for Clinical Research of the Donostia University Hospital, and patients signed a written consent for the use of the blood sample for biomedical research.
STATISTICAL ANALYSIS
Results were statistically analyzed using GraphPad Prism 6 statistical software. Data are shown as means 6 standard error of the mean. For comparisons between two groups, parametric Student t test or nonparametric Mann-Whitney test were used. For comparisons between more than two groups, parametric one-way analysis of variance or nonparametric Kruskal-Wallis tests followed by a posteriori Bonferroni or Dunn tests were used, respectively.
Results
REGULATION OF miR-506 PROMOTER ACTIVITY IN HUMAN CHOLANGIOCYTES
We previously reported that miR-506 expression is up-regulated in PBC cholangiocytes compared to normal human cholangiocytes. (8) Here, the regulatory activity of miR-506 promoter was evaluated in human cholangiocytes using recombinant luciferase reporter vectors containing a fragment of the promoter region. Three fragments of different length of the sequence located immediately 5 0 upstream of miR-506 were cloned and assayed (i.e., Z1 [3, 1A; Supporting Fig. S1 ) in the presence or absence of different proinflammatory, profibrotic, and/or promitotic molecules found overexpressed in PBC livers. As positive control, a recombinant vector containing the cytomegalovirus promoter was used (Fig. 1A) . Under basal conditions, the recombinant luciferase vector containing the Z1 (the longest fragment) miR-506 promoter showed 0 upstream of hsamiR-506, named Z1, Z2, and Z3 respectively, were cloned upstream of the beginning of transcription of the firefly luciferase coding sequence. The Z1 promoter show higher luminescence levels compared to Z2 and Z3 (n 5 10). The cytomegalovirus promoter was used as a positive control (n 5 10). (B) IL8, IL12, IL17, IL18, as well as TNFa increase the luciferase activity of promoter Z1 (n 5 10). (C) IL6, IL1b, 17b-estradiol, transforming growth factor-beta 1, IFNc, dexamethasone, epidermal growth factor, and bile acids (cholic acid, UDCA, tauroursodeoxycholic acid) did not influence Z1 promoter luciferase activity (n 5 10). Abbreviations: CA, cholic acid; CMV, cytomegalovirus; DE, dexamethasone; EGF, epidermal growth factor; 17b-est, 17b-estradiol; LUC, luciferase; TGFb1, transforming growth factor-beta 1; TUDCA, tauroursodeoxycholic acid.
higher expression of luciferase compared to both Z2 and Z3 fragments, whereas no differences in the activities were observed between Z2 and Z3 fragments (Fig.  1A) . The presence of proinflammatory cytokines IL8, IL12, IL17, IL18, or TNFa up-regulated luciferase expression in human cholangiocytes transfected with the Z1 recombinant vector (Fig. 1B) . Of note, these effects were absent in cells transfected with a Z2 or Z3 promoter fragment (Supporting Fig. S3 ). On the other hand, other proinflammatory (i.e., IL6, IL1b, and IFNc) and profibrotic (i.e., transforming growth factor b1) cytokines did not affect miR-506 Z1-promoter activity in cholangiocytes (Fig. 1C) . Finally, the presence of bile acids (i.e., cholic acid, UDCA, and tauroursodeoxycholic acid), estrogens (i.e., 17b-estradiol), glucocorticoids (i.e., dexamethasone), and growth factors (i.e., epidermal growth factor) did not affect the Z1-promoter activity in human cholangiocytes (Fig. 1C) .
EFFECT OF miR-506 ON THE PROTEOMIC PROFILE OF HUMAN CHOLANGIOCYTES
H69 cholangiocytes overexpressing miR-506 (H69-miR-506) or a negative control (H69-miR-neg) sequence under the regulation of a cytomegalovirus promoter were generated. We confirmed by real-time quantitative PCR that expression of the miR-506 precursor (pre-miR-506) resulted in increased expression of the mature miR-506 sequence compared to cells transfected with the pre-miR-neg or vehicle ( Fig. 2A) . We previously reported that transient transfection of miR-506 in H69 cholangiocytes resulted in downregulation of AE2 protein expression and activity. (8) As predicted, stable transfection of H69 cholangiocytes with recombinant vectors that overexpress pre-miR-506 also diminished AE2 protein expression compared to cells transfected with the pre-miR-neg or vehicle (Fig. 2B) . To elucidate the pathophysiological impact of miR-506 in cholangiocytes, a proteomic analysis was performed in H69, H69-miR-neg, and H69-miR-506 cells. Overexpression of miR-506 in human cholangiocytes prompted the dysregulation of multiple proteins compared to control conditions (Fig. 2C) . The dysregulated proteins were involved in different biological processes such as biological adhesion (i.e., COLGALT1), biological regulation (i.e., ATP1A1, DDX3X, and KPNA2), and cellular component organization or biogenesis (i.e., GSPT1, RPS19, OPA1, HSPA8, LMNA, CCT7, and ACTN1), among others, but mainly in mitochondrial metabolic processes (i.e., ALDH2, ACO2, OPA1, PDHB, SLC25A3, NNT, ATP5H, and ACLY) ( Fig. 2C-E) . In particular, the expression of three central mitochondrial proteins was validated by immunoblotting, confirming the down-regulation of OPA1 and ATP5H as well as the up-regulation of calpain 1 (CAPN1) in H69-miR-506 cells compared to controls (Fig. 2F) .
ROLE OF miR-506 IN THE BILIARY PHENOTYPE AND IN CHOLANGIOCYTE PROLIFERATION, ADHESION, AND MIGRATION
PBC cholangiocytes are characterized by dedifferentiation and linked to decreased expression of biliary (17) and epithelial markers and acquisition of proinflammatory, profibrotic, and mesenchymal (18) markers. In this regard, H69-miR-506 cells showed down-regulation of biliary (i.e., cytokeratin 7) and epithelial (i.e., zonula occludens-1) markers and increased expression of proinflammatory (i.e., IL8 and vascular endothelial growth factor), profibrotic (platelet-derived growth factor subunit B, transforming growth factor-beta 2, and alpha-smooth muscle actin), and mesenchymal (i.e., N-cadherin) markers compared to controls (Fig.  3A) . On the other hand, miR-506 decreased cell proliferation which was associated with the up-regulation of the cell cycle inhibitor p21 at the mRNA and protein levels compared to controls (Fig. 3B,C) . This altered phenotype also resulted in decreased adhesion and migration of cholangiocytes (Fig. 3D,E) .
INVOLVEMENT OF miR-506 IN CHOLANGIOCYTE STRESS AND APOPTOSIS
PBC cholangiocytes are characterized by cellular stress (19) and increased apoptosis. (20, 21) These PBC features are promoted by the down-regulation of AE2 and InsP3R3 in cholangiocytes. Thus, the lack of AE2 in PBC cholangiocytes sensitizes the cells to apoptosis induced by cytotoxic apolar hydrophobic bile acids, (22) and the down-regulation of InsP3R3 leads to altered ER-related Ca 21 signaling. (10, 12, 23) Because miR-506 directly targets both AE2 and InsP3R3 mRNAs, cellular stress and apoptosis were evaluated in H69-miR-506 cells and controls. MiR-506 increased the levels of ROS in cholangiocytes (Fig. 4A ) and up-regulated the expression of two key ER stress markers, inositolrequiring enzyme 1a and CCAAT-enhancer-binding protein homologous protein (Fig. 4B ), compared to controls; in contrast, expression of markers of other ER stress pathways such as activating transcription factor 6, PRKR-like ER kinase, or X-box binding protein 1 was found unchanged between the experimental groups (Supporting Fig. S4 ). All these pathological events were associated with protein up-regulation of the DNA damage marker phosphorylated histone H2A variant X protein (cH2AX) (Fig. 4C) but did not affect the baseline apoptosis of cholangiocytes compared to controls (Supporting Fig. S5 ). However, notably, miR-506 sensitized cholangiocytes to cell death induced by the toxic bile acids CDCA and glycochenodeoxycholic acid, measured by cell viability determinations (i.e., CellTiter-Glo [ Fig. 4D ] and WST-1 [ Supporting Fig. S6] ) and flow cytometrybased apoptotic assays (i.e., annexin-V and propidium iodide [ Fig. 4E; Supporting Fig. S7 ]) compared to controls. This bile acid-induced cell death is mainly mediated by apoptosis as the caspase inhibitor zVADfmk resulted in protection against the adverse effects of CDCA in cholangiocytes and the necroptosis inhibitor necrostatin-1 had no effect ( Fig. 4D,F; Supporting  Fig. S6 ). In this regard, CDCA stimulated p21 expression, caspase-3 activity, and cH2AX expression in H69-miR-506 cells (Fig. 4E) .
ROLE OF miR-506 IN MITOCHONDRIAL ENERGETIC METABOLISM IN CHOLANGIOCYTES
Because most of the proteins found dysregulated in cholangiocytes under miR-506 overexpression participate in metabolic processes (Fig. 2C,D) , mitochondrial metabolism was investigated in detail. Hence, OCR and ECAR were monitored upon sequential treatment with mitochondrial inhibitors in H69, H69-miR-neg, and H69-miR-506 cells using a Seahorse XF96 Extracellular Flux Analyzer (Fig. 5A) . MiR-506 altered mitochondrial energetic metabolism in cholangiocytes characterized by increased baseline respiration, maximal respiration, ATP-linked respiration, and nonmitochondrial respiration compared to controls (Fig. 5B) . In addition, H69-miR-506 cells showed increased ECAR, glycolysis, and oxidative phosphorylation and a more energetic phenotype compared to controls (Fig.  5C) . Notably, all of these functional events in H69-miR-506 cells were also associated with increased proton leak compared to controls (Fig. 5B) , indicating higher uncoupling of mitochondrial ATP production from respiration in H69-miR-506 cells that results in overall decreased ATP production (Fig. 5D) . The increased uncoupled respiration in H69-miR-506 cells (E) Representative images and corresponding quantification of cell migration analysis using transwell assays (n 5 5). Abbreviations: CK7, cytokeratin 7; PDGF, platelet-derived growth factor; aSMA, alpha smooth muscle actin; TGFb2, transforming growth factor-beta 2; VEGF, vascular endothelial growth factor; ZO1, zonula occludens 1.
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was confirmed by up-regulation of mitochondrial uncoupling protein 1 (UCP1) and UCP2 gene expression in H69-miR-506 cells compared to controls (Fig.  5E ). These functional data were supported by the fact that different proteins involved in the mitochondrial energetic metabolism were found altered by proteomic analysis in cholangiocytes under miR-506 overexpression, particularly proteins involved in mitochondrial energetic metabolism.
RELEVANCE OF miR-506 FOR PDC-E2 EXPRESSION IN CHOLANGIOCYTES AND FOR IMMUNE REGULATION
PBC patients are mostly characterized (95%) by spontaneous development of AMA specific against PDC-E2, as a consequence of the overexpression and mislocalization of PDC-E2 in cholangiocytes, resulting in autoimmune phenomena. (24) Here, we found that H69-miR-506 cells in baseline conditions present PDC-E2 overexpression (Fig. 6A,B) , which was located in both the cytoplasm and plasma membrane compared to control conditions, where PDC-E2 was mainly localized in the cytoplasm (Fig. 6B) . Next, cocultures of H69, H69-miR-neg, or H69-miR-506 cells together with PBC PBMCs were carried out and the proliferation and activation of immunocytes studied. Cocultures of H69-miR-506 cholangiocytes together with PBMCs from a PBC patient induced the generation of a higher number and size of lymphocyte aggregates compared to control conditions (Fig. 6C) . Notably, these lymphocyte aggregates were characterized by increased proliferation (carboxyfluorescein succinimidyl ester assay by flow cytometry; Fig.  6D ) and activation (cluster of differentiation 25 marker by flow cytometry; Fig. 6E ) of PBC PBMCs compared to controls. Likewise, coculture of H69-miR-506 cholangiocytes together with PBMCs from a normal human donor also increased the proliferation and activation of PBMCs compared to controls (Supporting Fig. S8 ). The levels of cytokines involved in the immune response of PBC patients were also evaluated in the supernatant of the cells cultured alone or cocultured with PBMCs from PBC patients. When cocultured, H69-miR-506 cells showed higher levels of both IL17A and IL23 compared to controls (Fig. 6F ).
Discussion
The key findings reported here are related to the regulatory mechanisms of miR-506 expression in human cholangiocytes as well as to the role of miR-506 in cholangiocyte pathophysiology and immune activation. Our data indicate that (i) miR-506 gene promoter activity is stimulated in cholangiocytes by different proinflammatory cytokines but not by bile acids, estrogens, or growth factors; (ii) stable overexpression of miR-506 in cholangiocytes inhibited AE2 protein expression and dysregulated the proteomic profile of the cells; and (iii) miR-506 inhibited the expression of biliary and epithelial markers in cholangiocytes and promoted the expression of mesenchymal, proinflammatory, profibrotic, and senescence genes. This altered phenotype resulted in decreased cell proliferation, adhesion, and migration; (iv) miR-506 stimulated ROS, ER stress, and DNA damage in cholangiocytes and sensitized the cells against toxic bile acid-induced apoptosis; (v) miR-506 increased the mitochondrial metabolism and oxidative phosphorylation associated with uncoupling of ATP production from mitochondrial respiration. These mitochondrial events were also associated with overexpression and mislocalization of PDC-E2; and (vi) miR-506 in cholangiocytes promoted the proliferation and activation of PBC lymphocytes. Our data are consistent with the notion that miR-506 is a key player in the pathogenesis of PBC and a potential target for therapy. PBC is characterized by dysregulation of the miR expression profile in both liver and PBMCs, (25, 26) but their functional relevance remains mostly unknown. In this regard, we previously found that miR-506 is exclusively expressed in the bile duct epithelial cells of PBC livers and that its expression is increased compared to the bile duct cells of normal controls. (8) In cholangiocytes, miR-506 directly targets both AE2 (8) and Ins3PR3, (12) leading to cholestasis. (12, 27, 28) However, the regulation of miR-506 expression and its role in cholangiocyte pathophysiology and immune regulation remain unknown. In the current report, the evaluation of different lengths of miR-506 promoter indicates that the full-length 3-kb region of miR-506 promoter is required for its stimulation by proinflammatory cytokines found overexpressed in PBC livers such as IL8, IL12, IL17, IL18, and TNFa. These proinflammatory cytokines are involved in PBC immune response modulation and are associated with disease progression. (18, (29) (30) (31) (32) Thus, in PBC patients, the cytokine profile in serum and liver samples suggests activation and liver recruitment of T helper 1 (Th1) and Th17 cells. (30) lL12 and IL23, which are produced by antigen presenting cells, are responsible for promoting Th1 and Th17 immune responses, respectively. IL12 primarily promotes the differentiation of Th0 to Th1 cells (which are known to produce IFNc, IL18 and TNFa), whereas IL23 is implicated in the differentiation of Th0 to Th17 that induces IL17 secretion. (33, 34) In contrast, other pro-inflammatory or pro-fibrotic cytokines, as well as estrogens -believed to participate in the pathogenesis of this disease that mainly affects middle-aged women-growth factors, immunosuppressors, and choleretic but potentially cytotoxic (i.e., cholic acid) or hypercholeretic and hepatoprotective (i.e., UDCA and tauroursodeoxycholic acid) bile acids did not show any effect on miR-506 expression. These data indicate that the full-length promoter sequence contains essential regulatory elements for the specific regulation of miR-506 expression in cholangiocytes under baseline and stimulated conditions and highlight the importance of specific proinflammatory cytokines in the promotion of miR-506 expression.
FIG. 6. (Continued).
ERICE, MUNOZ-GARRIDO, ET AL. HEPATOLOGY, April 2018
We further evaluated the role of miR-506 in cholangiocyte pathophysiology. Experimental overexpression of miR-506 in cholangiocytes induced the dysregulation of proteins involved in fundamental biological processes. In particular, expression of the mitochondrial proteins OPA1, ATP5H, and CAPN1 was further validated by FIG. 7 . Working model. Proinflammatory cytokines such as IL8, IL12, IL17, IL18, and TNFa stimulate the promoter activity of the miR-506 gene. Overexpression of miR-506 in cholangiocytes inhibits AE2 and Ins3PR3 expression and activities, resulting in altered intracellular pH and Ca 21 concentration. MiR-506 leads to altered mitochondrial energetic metabolism associated with altered expression of proteins involved in such a process; the resultant mitochondrial energetic metabolism fails and results in decreased ATP production and in overexpression and mislocalization of PDC-E2, leading to immune activation. MiR-506 decreases the expression of biliary and epithelial markers in cholangiocytes and increases the expression of mesenchymal, inflammatory, and senescence genes, impairing cell proliferation, adhesion, and migration and stimulating ROS, ER stress, and DNA damage. MiR-506 also sensitizes cholangiocytes against toxic bile acid-induced apoptosis.
immunoblotting as down-regulated (OPA1 and ATP5H) or up-regulated (CAPN1) compared to controls. The abnormal expression of OPA1, ATP5H, and CAPN1 has been described to be involved in the generation of ER stress and/or ROS. (35) (36) (37) Additionally, miR-506 decreased the gene expression of biliary/epithelial markers and up-regulated mesenchymal, proinflammatory, and profibrotic genes in cholangiocytes. In line with this, miR-506 inhibited cholangiocyte proliferation, adhesion, and migration. These results mimic the phenotype of PBC cholangiocytes, which are characterized by dedifferentiation, inflammation, and a profibrogenic phenotype. (34) Bile ducts in PBC livers show senescence, DNA damage, and ER stress. (19, 38, 39) In agreement with these PBC features, our data indicate that miR-506 induces cell senescence by increasing p21 expression and stimulates cellular stress by increasing ROS levels, ER stress, and DNA damage; this altered phenotype did not result in baseline cholangiocyte cell death but sensitized cells against the caspase-3-dependent apoptosis induced by toxic bile acids. In contrast, the necrotic cell death pathway "necroptosis," which was reported to be active in hepatocytes of an acute cholestatic animal model and PBC patients, (40) did not have any role in bile acid-induced cholangiocyte death. The proapoptotic effect of miR-506 may be related, to a certain degree, to its direct targeting of AE2 mRNA as experimental down-regulation of AE2 in cholangiocytes has been shown to favor bile salt-induced apoptosis. (41) Moreover, glycochenodeoxycholic acid has been described to reduce AE2 expression in biliary epithelial cells by inducing ROS. (42) These data pointed out the relevant role of miR-506 regulating the so-called AE2-related biliary bicarbonate umbrella. AE2 downregulation impairs this protective barrier, resulting in increased intracellular pH, accumulated toxic apolar hydrophobic bile acids, and cell apoptosis. (43) All of these PBC-like features observed in miR-506 overexpressing cholangiocytes may be responsible, at least partially, for the progressive ductopenia characteristic of the patients. (38) The role of miR-506 was also evaluated in mitochondrial metabolic activity and immune activation. Mitochondrial abnormalities are involved in the pathogenesis of PBC. Toxic bile acid accumulation during cholestasis leads to mitochondrial dysfunction through oxidative stress. (44) Our data showed that overexpression of miR-506 in cholangiocytes led to altered mitochondrial energetic metabolism characterized by increased oxygen consumption and glycolysis but also by increased proton leak, indicating a rise of uncoupling respiration. This increase in uncoupling could be in line with the increase in ROS production and perhaps with DNA damage and ER stress. Of note, miR-506-dependent mitochondrial dysfunction in cholangiocytes was also associated with PDC-E2 overexpression, a typical PBC feature that may promote, at least partially, the immunogenicity of cholangiocytes.
(34) Therefore, we evaluated the capacity of miR-506 in cholangiocytes to modulate PBC lymphocytes under coculture. Interestingly, miR-506 overexpressing cholangiocytes promoted the proliferation and activation of PBC PBMCs compared to cholangiocytes under control conditions. In addition, cocultures of H69-miR-506 cells and PBMCs increased both IL17 and IL23 levels, important cytokines in Th1 and Th17 immune responses and in PBC, as these proinflammatory cytokines are overexpressed in peripheral blood of PBC patients. (31) Of note, miR-506 overexpressing cholangiocytes also stimulated the proliferation and activation of PBMCs from a normal human donor compared to cholangiocytes under control conditions, suggesting that up-regulation of miR-506 in PBC cholangiocytes may be an important cause of immune activation. Therefore, PBC cholangiocytes appear not to be mere targets of an altered immune system and may be crucial in the promotion of immune reactions. These data are consistent with previous reports indicating that PBC cholangiocytes are characterized by overexpression and aberrant location, into the plasma membrane, of mitochondrial PDC-E2. Additionally, PBC cholangiocytes present increased apoptosis (20, 21) and immunologically active PDC-E2 due to the lack of glutathiolation, (45) which may be present in apoptotic bodies (known as apotopes). (45, 46) These two mechanisms of aberrant PDC-E2 presentation may be the base of the development of AMA and further promotion of autoimmunity against cholangiocytes.
In summary, this study provides insights into the important role of miR-506 in the pathogenesis of PBC. Different proinflammatory cytokines found overexpressed in PBC livers promote the up-regulation of miR-506 expression in cholangiocytes, leading to the development of PBC-like features such as cell dedifferentiation, stress, predisposition to bile saltinduced apoptosis, alterations in mitochondrial function, and PDC-E2 overexpression, which finally result in PBC immune activation (Fig. 7) . These effects are mediated, to a certain degree, by direct targeting of miR-506 to both AE2 and Ins3PR3, which play key roles in the maintenance of the biliary phenotype. However, the role of miR-506 in the direct regulation of the expression of other genes must also be considered and determined in future studies. MiR-506 represents a key player in the pathophysiology of PBC cholangiocytes and a potential target for therapy.
